Is antithrombin treatment of disseminated intravascular coagulation a quixotic goal?

Area of Science:

• Critical Care Medicine
• Hematology
• Pharmacology

Background:

• Disseminated intravascular coagulation (DIC) complicates sepsis and increases mortality.
• Antithrombin (AT) has been investigated as a treatment for sepsis-related DIC without proven benefit in prior randomized trials.
• Lower AT doses were explored in a recent retrospective study.

Purpose of the Study:

• To evaluate the efficacy of two lower doses of antithrombin (AT) concentrate in patients with sepsis-related disseminated intravascular coagulation (DIC).

Main Methods:

• A retrospective review of patients with sepsis-related DIC and baseline antithrombin activity <40%.
• Patients received either 1,500 IU/day (n=259) or 3,000 IU/day (n=48) of AT concentrate for 3 days.
• No placebo group was included in the analysis.

Main Results:

• The group receiving 3,000 IU/day of AT demonstrated higher 28-day survival rates compared to the 1,500 IU/day group.
• A higher rate of DIC resolution was observed in the higher-dose AT group.
• Baseline differences in confounders were present due to the retrospective, non-randomized design.

Conclusions:

• The study suggests a potential benefit of higher doses of AT concentrate in sepsis-related DIC, indicated by improved survival and DIC resolution.
• Findings are limited by the retrospective nature, lack of randomization, absence of a placebo group, and potential confounding factors.
• Further randomized controlled trials are warranted to confirm the efficacy and safety of AT in sepsis-related DIC.